Implementation and value of biomarkers in early development

Jan. 5, 2012 - PRLog -- SMi presents their 5th annual
Biomarkers Summit
16/17 January 2012, Copthorne Tara Hotel, London, United Kingdom  

The speaker line-up is made up of expert s from all over the industry, providing a variety of different viewpoints across different therapeutic areas; this event is not to be missed.

Key Presentations Include:

Implementation and value of biomarkers in early development
•   Proof of principle by demonstrating target activity modulation, based on pharmacodynamic markers based on sample and assay quality
•   Identification of sensitive tumours using predicitive biomarkers
•   Discussing target related, sensitivity "signatures", application for proof of concept (disease modulation) and companion diagnostic issues
Hans Winkler, Senior Director Translational Research, Oncology, J & JPRD

Importance of patient stratification in delivering new therapeutics
•   A one size all approach doesn’t yield ideal results:
    o Lessons from mepolizumab
•   Asthma is a heterogeneous disease
    o SARP, Leicester, Woodruff/UCSF data
•   Stratification approaches yield results and is the likely future paradigm
    o Mepolizumab, AMG-317, aerovant, lebrikizumab
Richard May, Head of Biology - Respiratory, MedImmune

Development and Application of Clinical Safety Biomarkers with a focus on Imaging biomarkers
•   Clinical safety biomarkers – definitions and key principles
•   Development, validation and qualification of safety biomarkers for clinical use
•   Utility of imaging methods for clinical safety biomarker applications
•   Examples of imaging as clinical safety biomarkers in drug development
Magnus Nord, Associate Professor, Safety Science Physician, AstraZeneca

To view the full conference programme please visit http://www.smi-online.co.uk/biomarkers37.asp